ESGO 2020

Survival outcomes are not worse for patients with endothelial ovarian cancer treated with neoadjuvant chemotherapy if cytoreduction surgery is delayed beyond 3 cycles of treatment. Read More ›

Niraparib improved progression-free survival when used as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer with BRCA wild-type tumors, regardless of homologous recombination status. Read More ›

Early preoperative PET-CT examination in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy may be a useful prognostic tool. Read More ›

Inhibition of AKT or DNA-PK in combination with cisplatin results in reduced cell growth and proliferation. The use of AKT and DNA-PK inhibitors may improve overall survival for patients with platinum-resistant high-grade serous ovarian cancer. Read More ›

Pathways were identified that are crucial in the mechanism of PARP inhibitor resistance in patients with ovarian cancer. Key signaling kinases were identified as therapeutic targets and folate receptor 1 was identified as a potential biomarker for treatment response. Read More ›

Insulin-like growth factor binding protein-2 (IGFBP2) was demonstrated to be a potential biomarker for the diagnosis of ovarian cancer. The assessment of preoperative serum IGFBP2 levels in patients with adnexal mass may have the potential to differentiate between malignant and benign ovarian tumors. Read More ›

The combined assessment of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio increases their prognostic value in patients with advanced-stage ovarian cancer. This combined prognostic factor may be useful in improving immunotherapy strategies in patients with advanced ovarian cancer. Read More ›

This study could not confirm a favorable response to neoadjuvant chemotherapy or less extensive surgery in patients with a BRCA mutation. However, the data demonstrate that complete surgical cytoreduction is vital in achieving better survival outcomes in women with advanced ovarian cancer, irrespective of BRCA status. Read More ›

The incidence of hematologic adverse events observed in patients with advanced ovarian cancer treated with niraparib at an individualized starting dose of 200 mg once daily was lower than that reported with a dose of 300 mg once daily. Read More ›

An analysis of real-world data suggests that patients with a platinum-free interval of ≥12 months experienced a trend toward a greater benefit from subsequent platinum-based chemotherapy after PARP inhibition. For patients with a platinum-free interval of 6 to 12 months, the benefit was similar to that seen in patients receiving nonplatinum chemotherapy. Read More ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive: